What Is Growth Hormone? Definition and What Research Reports

Plain definition

Growth hormone (GH) is a hormone made and released by the pituitary gland, a small structure at the base of the brain. In children it is one of the main signals that tells bones and other tissues to grow, and in adults it continues to influence how the body handles fat, muscle and energy. It is a peptide hormone — a chain of amino acids — rather than a steroid, which is why it is discussed so often on peptide-focused sites. The name used in pharmacology and older literature is somatotropin; when produced by recombinant technology as a medicine it is often written as rhGH or somatropin.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question, symptom or treatment decision. Nothing here describes how growth hormone or any related peptide should be used.

Growth hormone in biochemical and regulatory terms

GH is a single-chain polypeptide secreted by somatotroph cells of the anterior pituitary. Reference physiology summaries described secretion as pulsatile rather than continuous, controlled by two opposing hypothalamic signals — growth hormone-releasing hormone (GHRH), which stimulates release, and somatostatin, which restrains it — with feedback from IGF-1 and from GH itself (PMID 29489209). Because secretion is episodic, a single blood measurement is a poor description of total output, and the literature on assessing GH status relies on stimulation and profiling approaches rather than one-off values (PMID 29489209).

How the signal is transmitted

GH exerts effects by binding the growth hormone receptor (GHR) on target cells, which activates intracellular signalling and, in the liver and other tissues, drives production of insulin-like growth factor 1 (IGF-1). Much of GH's growth-promoting action is therefore described as indirect. Reviews of animal models in which the GHR gene was disrupted reported that removing the receptor changes body size and metabolic phenotype, and researchers used those models to separate receptor-dependent effects from effects attributed to GH acting on other pathways (PMID 37717983).

Where GH sits in childhood growth

A review of childhood growth physiology placed GH within a wider hormonal system: the GH/IGF-1 axis operates alongside thyroid hormone, sex steroids at puberty, glucocorticoids and nutritional signals, and the review reported that normal linear growth depends on the interaction of these systems rather than on GH alone (PMID 28437784). That framing matters for reading popular claims, because "growth hormone" is frequently treated online as a single master switch for height, muscle or youthfulness, which the growth-physiology literature does not support (PMID 28437784).

Sleep and the timing of release

Sleep has long been associated with the largest GH pulses. A 2025 study described a neuroendocrine circuit linking sleep state to growth hormone release, and the researchers characterised how the sleep-related neural signal was coupled to pulsatile secretion (PMID 40562026). The study is mechanistic work on the circuitry of secretion; it did not evaluate any product or regimen (PMID 40562026).

How the term is used in peptide research — and where it is misused

In research writing, "growth hormone" normally means the endogenous hormone or a recombinant version of it. Several related terms are often collapsed into it incorrectly:

• "GH" used to mean a secretagogue. Peptides described as growth hormone secretagogues are named for the signalling pathway they target (GHRH receptor or the ghrelin/GHS receptor), not because they are growth hormone. None of the papers summarised on this page characterised specific secretagogue products, so PeptideU does not attribute effects to them here.
• "GH" used interchangeably with IGF-1. These are distinct molecules with distinct receptors; reviews of doping endocrinology treated GH and IGF-1 as separate agents with separate detection problems (PMID 36736729).
• "GH deficiency" used loosely. In clinical literature the term refers to a defined diagnosis with biochemical criteria, including specific frameworks for re-testing adolescents moving into adult care (PMID 38557372). It is not a synonym for fatigue or for age-related decline.
• "Anti-aging hormone." A 2023 review on growth hormone and aging discussed the age-related decline in GH output and reported that the balance of benefit and risk for interventions in older adults remained contested (PMID 36948778).

Related terms

What the published literature reports about growth hormone

Deficiency states

A review of adult growth hormone deficiency from transition to senescence described GH deficiency as a condition with consequences beyond stature, discussing body composition, metabolic features and quality-of-life measures, and it reported that the clinical picture and management questions differ across life stages (PMID 30378784). Work focused specifically on the transition period addressed how adolescents treated in childhood are re-evaluated before adult care decisions, and the authors reported that not all childhood diagnoses persist on retesting (PMID 38557372). Deficiency can also be structural in origin: a case report described a hypothalamic lipoma associated with growth hormone deficiency, illustrating that imaging findings sometimes explain an endocrine picture (PMID 32042280).

Nervous system

GH signalling is not limited to bone and muscle. A review of growth hormone and synaptogenesis summarised evidence that GH influences synapse formation and neural plasticity, and the authors reported neural actions as a distinct area of GH biology from somatic growth (PMID 32723552). Separately, a paper examining epilepsy, depression and growth hormone explored intersections between seizure disorders, mood and the GH axis (PMID 30773449).

Reproductive research

GH has been investigated in reproductive medicine. A review on growth hormone and endometrial receptivity surveyed the proposed roles of GH signalling in the endometrium and reported that the clinical evidence base in this area was still developing (PMID 31616379).

Aging

Reviews of GH and aging described a decline in pulsatile GH output with age and discussed the tension in the field: animal models with reduced GH signalling have been studied for longevity phenotypes, while intervention in older humans raises metabolic and safety questions (PMID 36948778). Receptor-disruption models were reviewed in the same conceptual space, since reducing GH receptor signalling produced phenotypes that researchers examined in relation to body size and lifespan (PMID 37717983).

Misuse in sport and safety concerns: What Studies Report

A 2023 review of doping and sports endocrinology covered growth hormone alongside IGF-1, insulin and erythropoietin. The authors reported that these agents are misused with the expectation of performance or physique benefit, discussed the analytical difficulty of detecting GH misuse, and set out the health risks and endocrine consequences attributed to non-medical use (PMID 36736729). Clinical reviews of GH in adults similarly framed treatment as a physician-supervised decision with monitoring requirements rather than a general-purpose intervention (PMID 30378784, PMID 36948778).

Regulatory context

Recombinant human growth hormone products are prescription medicines approved for defined indications; growth hormone is also on prohibited-substance lists in regulated sport, which is why detection methodology features prominently in the doping literature (PMID 36736729). Many peptides sold to researchers are labelled research-use-only and are not approved medicines. This page describes literature and regulatory categories only; it does not describe availability or use.

References

• Physiology, Growth Hormone (StatPearls, 2026)
• The Physiology of Childhood Growth: Hormonal Regulation (Hormone Research in Paediatrics, 2017)
• Neuroendocrine circuit for sleep-dependent growth hormone release (Cell, 2025)
• Growth hormone receptor gene disruption (Vitamins and Hormones, 2023)
• Growth hormone (GH) and synaptogenesis (Vitamins and Hormones, 2020)
• Adult Growth Hormone Deficiency: from Transition to Senescence (Pediatric Endocrinology Reviews, 2018)
• Management of transition growth hormone deficiency (Chinese Journal of Contemporary Pediatrics, 2024)
• Hypothalamic lipoma and growth hormone deficiency (International Journal of Pediatric Endocrinology, 2020)
• Growth Hormone and Endometrial Receptivity (Frontiers in Endocrinology, 2019)
• Growth Hormone and Aging (Endocrinology and Metabolism Clinics of North America, 2023)
• Epilepsy, depression, and growth hormone (Epilepsy & Behavior, 2019)
• Doping and sports endocrinology: growth hormone, IGF-1, insulin, and erythropoietin (Revista Clinica Espanola, 2023)